NIH PAR · NCI · U01
PAR-28-056: Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
Through this Notice of Funding Opportunity (NOFO), NCI solicits applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the NCI's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma (PDAC). The PCDC will support research for the development and testing of new molecular and imaging biomarkers for detecting PDAC early and for…
- NOFO number
- PAR-28-056
- Type
- PAR
- Activity code
- U01
- Primary institute
- NCI · National Cancer Institute
- Clinical trials
- Optional
- Posted
- Sep 25, 2026
- Opens
- Jan 5, 2027
- Expires
- Nov 6, 2029
PAR-28-056 due dates
9 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 05, 2027 * | March 05, 2027 * | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 05, 2027 * | July 05, 2027 * | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 05, 2027 * | November 05, 2027 * | Not Applicable | March 2028 | May 2028 | July 2028 |
| February 05, 2028 * | March 05, 2028 * | Not Applicable | July 2028 | October 2028 | December 2028 |
| June 05, 2028 * | July 05, 2028 * | Not Applicable | November 2028 | January 2029 | April 2029 |
| October 05, 2028 * | November 05, 2028 * | Not Applicable | March 2029 | May 2029 | July 2029 |
| February 05, 2029 * | March 05, 2029 * | Not Applicable | July 2029 | October 2029 | December 2029 |
| June 05, 2029 * | July 05, 2029 * | Not Applicable | November 2029 | January 2030 | April 2030 |
| October 05, 2029 * | November 05, 2029 * | Not Applicable | March 2030 | May 2030 | July 2030 |
What its predecessor PAR-21-334 funded
PAR-28-056 reissues PAR-21-334. Until awards appear under the new number, its funding history is the best guide to who wins under this program: 10 projects and $32.0M in FY2022–FY2026.
Projects funded
10
Distinct projects, FY2022–FY2026
New awards
4
Type 1 (new project) award records
NIH funding
$32.0M
Award dollars under PAR-21-334, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 4 | 0 | $3.4M |
| FY2023 | 8 | 3 | $6.4M |
| FY2024 | 9 | 1 | $6.8M |
| FY2025 | 12 | 0 | $7.4M |
| FY2026 | 12 | 0 | $8.1M |
Institutions with the most funding
- Johns Hopkins University$6.6M · 2 projects
- Dana-Farber Cancer Inst$4.2M · 1 project
- University of Nebraska Medical Center$4.1M · 1 project
- Mayo Clinic Rochester$3.8M · 1 project
- Beckman Research Institute/City of Hope$3.5M · 1 project
- Oregon Health & Science University$3.3M · 1 project
- University of Tx MD Anderson Can Ctr$2.8M · 1 project
- University of California, San Francisco$2.1M · 1 project
Funding institutes
- NCI$32.0M · 45
Activity codes funded
- U0145 records
Most recent new awards
- Using microvolumetric cyst fluid proteolysis for early detection of pancreatic cancer (opens NIH RePORTER)
University of California, San Francisco · 1U01CA282269-01A1 · NCI · Notice May 20, 2024
$812KU01
- Biomarker Validation in Pancreatic Cystic Neoplasms (opens NIH RePORTER)
New York University School of Medicine · 1U01CA282272-01 · NCI · Notice Sep 14, 2023
$898KU01
- Development of a panel of multiplex biomarkers for the early detection of pancreatic ductal adenocarcinoma and high-risk lesions (opens NIH RePORTER)
Johns Hopkins University · 1U01CA274514-01A1 · NCI · Notice Jul 19, 2023
$825KU01
- Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs (opens NIH RePORTER)
Oregon Health & Science University · 1U01CA278923-01 · NCI · Notice May 15, 2023
$767KU01
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-28-056. Contact the program officer at the institute that fits your research before applying.
- NCI · National Cancer Institute
- none
Related notices
NIH lists no related notices for PAR-28-056 yet.
Award terms
- Application types allowed
- New Renewal Resubmission Revision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budget should not exceed 600K direct costs per year and need to reflect the actual needs of the proposed project.
- Project period
- The project period is 5 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-21-334.
- Companion NOFOs: PAR-28-057.
Other open NOFOs for U01
- RFA-CA-27-019Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)NCI · next due Oct 19, 2026
- PAR-25-325Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)NCI · next due Feb 4, 2027
- PAR-27-073Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
- PAR-25-248Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)NCI · next due Feb 10, 2027
- PAR-26-134The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)NCI · next due Jun 5, 2027
- PAR-24-325Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)NIBIB · next due Jan 27, 2027
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.